You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Exosomal Circular RNAs in Thyroid Cancer: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lindsay Dong and Version 1 by Eman Toraih.

Thyroid cancer (TC) is the most common endocrine tumor. The genetic and epigenetic molecular alterations of TC have become more evident in recent years. However, a deeper understanding of the roles these molecular changes play in TC tumorigenesis and progression is essential in developing a successful treatment strategy and improving patients’ prognoses. Circular RNAs (circRNAs), a family of non-coding RNAs, have been implicated in several aspects of carcinogenesis in multiple cancers, including TC. 

  • circular RNAs
  • circRNA
  • diagnosis
  • exosomal circRNAs

1. Introduction

Thyroid cancer (TC) is the most prevalent endocrine-related neoplasm, and its incidence continues to increase [1]. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting for nearly 85% of cases [2].
Non-coding RNAs (ncRNAs) are non-protein coding transcripts that can be classified into two main types: small ncRNAs (18–200 nucleotides) and long ncRNAs (lncRNAs, >200 nucleotides) [4,5][3][4]. The microRNA family (miRNAs; 22–25 nucleotides) belongs to the former class, binding to miRNA response elements (MREs) in the 3′-untranslated region (3′-UTR) of the target messenger RNA (mRNA) to induce mRNA degradation and/or suppress its translation into protein [6,7][5][6]. Circular RNAs (circRNAs) have emerged as a large family of endogenous ncRNA transcripts widely expressed in different cellular contexts and can act as post-transcriptional regulators. They are generated by head-to-tail splicing that has neither 5′–3′ polarities nor a polyadenylated tail, thus exhibiting a covalently closed loop structure [8,9][7][8]. Most circRNAs are derived from the gene’s exon region, but a small percentage are created by intron cleavage [10][9]. They were first identified in humans nearly 40 years ago using electron microscopy [8][7]. Initially, circRNAs were misinterpreted as splicing errors and transcriptional artifacts [11,12,13][10][11][12]. Given the recent advances in high-throughput sequencing and bioinformatics analyses, thousands of circRNAs have been recognized as abundant stable ncRNAs in various species and cell lines [14][13].

2. Exosomal Circular RNAs in Thyroid Cancer

2.1. Diagnostic and Prognostic Utility of circRNAs in TC Patients

In the last decade, circRNAs have received much attention as key players in cancer development and progression, supporting their utility as biomarkers for cancer diagnosis or monitoring [42][14]. Because of their closed-loop structure, circRNAs have a high level of stability and resistance to degradation [20,35][15][16] and are thus likely to be promising biomarkers for PTC. Many circRNAs show increased expression levels in TC tissues and cell lines compared with adjacent non-cancer tissues, normal tissues, and normal cell lines and promote tumor development. The “circRNA pleckstrin and Sec7 domain containing 3 (circ_PSD3)” were aberrantly upregulated in PTC tumor tissues compared with adjacent normal tissues [109][17]. Overexpression of hsa_circ_0011290 in PTC compared with matched para-cancerous thyroid tissues was associated with advanced stage and poor prognosis of PTC [32][18]. Yao et al. demonstrated that overexpression of circ_0058124 in PTC tissues was associated with malignant features and poor outcomes in PTC patients in terms of advanced tumor-node-metastasis (TNM) stage, tumor size, LN metastasis, extrathyroidal extension, and distant metastasis [110][19]. Upregulation of circ_0005273 was reported in PTC tissues and was related to poor survival [64][20]. Overexpression of circ_BACH2 was reported in PTC tissues compared with adjacent tissues and was closely linked to larger tumor size, advanced TNM stage, lymph node metastasis, and shorter survival times [3][21]. Upregulated circ_0008274 was associated with poor PTC prognosis. Overexpression was associated with advanced TNM stage, tumor infiltration, and lymph node metastasis [111,112][22][23]. Similarly, circ_0067934 overexpression in TC tissues was associated with larger tumor size, higher AJCC stage, lymph node metastasis, and shorter survival times [113][24]. Wang et al. reported a lower level of circRNA itchy E3 ubiquitin-protein ligase (circ-ITCH) expressed in PTC tissues than in normal adjacent tissues [71][25]. In addition, circ_0137287 was downregulated in PTC tissues and related to aggressive clinical pathologic features in PTC patients, such as larger tumor size, advanced T stage, lymph node metastasis, and extrathyroidal extension [114][26].

2.2. Circular RNAs Mediate Tumor Progression In Vivo and In Vitro

Emerging evidence suggests that some circRNAs play a significant role in tumor progression via multiple mechanisms, such as cell proliferation, differentiation, autophagy [119[27][28],120], EMT [56[29][30][31][32],78,121,122], immune modulation [51][33], apoptosis [114][26], vascularization [123][34], invasion, and metastasis [120,124][28][35]. The circRNAs–miRNA–mRNA axis can deregulate various cancer-related signaling pathways [29,125][36][37] (Figure 41).
/media/item_content/202210/6341104dd0442cancers-14-04728-g004.png
Figure 41. In vitro cell lines were used to study circRNA expression [126,127,128,129].
In vitro cell lines were used to study circRNA expression [38][39][40][41].

32.2.1. Tumor-Suppression-Related circRNAs

Some circRNAs were found to exert an anti-tumor function in PTC. In a microarray experiment, downregulated circRNA_100395 was observed in six PTC tumors compared with matched contralateral normal tissues. Circ_100395 showed interactive potential with two cancer-related miRNAs (miR-141-3p and miR-200a-3p), suggesting a role for the “hsa_circRNA_100395/miR-141-3p/miR-200a-3p” axis in PTC pathogenesis [130][42]. Moreover, downregulation of circ-ITCH was reported in “K1, IHH-4, and TCP-1” PTC cell lines [71][25]. Circ-ITCH promoted apoptosis in vitro and inhibited cancer cell proliferation in vivo, based on gain-of-functional assays. Circ-ITCH upregulates the expression of “casitas B-lineage lymphoma (CBL)”, an E3 ligase of nuclear β-catenin, by sponging miR-22-3p. Elevated levels of CBL suppressed the Wnt/β-catenin pathway activity with subsequent inhibition of PTC progression [71][25].

32.2.2. Tumorigenesis-Related circRNAs

Other upregulated circRNAs are known to promote tumor growth (Table 3). CircTP53 is upregulated in TC cell lines, and this overexpression is associated with increased cancer cell proliferation and viability of TPC-1 cells. CircTP53 sponge miR-1233-3p thus increased “mouse double minute 2 (MDM2)” expression and downregulates the protein level of p53. Knockdown of circTP53 inhibited the expression of MDM2 and increased the protein level of p53 [30][43]. Jin and colleagues reported that circ_0004458 was overexpressed in PTC tissues and was associated with tumor size, invasion, lymphatic infiltration, and distal metastasis. Furthermore, expression levels were upregulated in different TC cells (BCPAP, TPC-1, K1, and IHH4) compared with NORI cells. In contrast, circ_0004458 silenced suppressed cell growth and enhanced apoptosis and cell cycle arrest in PTC cell lines in vitro, and hampered tumor growth in nude mice by inhibiting miR-885-5p and activating “Rac family small GTPase 1 (RAC1)” [116][44]. Circ-LDLR is overexpressed in PTC tissues/cells. This overexpression regulated Lipase H (LIPH) expression by sponging miR-195-5p. Knockdown of this circRNA suppressed PTC cells’ malignant behaviors and promoted PTC cell colony apoptosis in vivo [132][45]. Circ_ZFR was also implicated in thyroid cancer. It can sponge and silence miR-1261, allowing the activation of the transcriptional and immune response regulator C8orf4 and triggering cancer cell growth [31][46]. The role of circ_102171 in PTC tissues and cell lines (TPC-1, NPA87, KAT-5) has also been examined. Higher expression was shown in PTC samples. Circ_102171 accelerated PTC progression by modulating “CTNNB1P1-dependent beta-catenin” pathway activation. It can target CTNNBIP1 by suppressing the “β-catenin/TCF3/TCF4/LEF1” pathway to initiate the “Wnt/β-catenin” pathway and progression of PTC. CircRNA_102171 downregulation decreased cell proliferation/migration and triggered apoptosis in vivo and in vitro [27][47]. Circ_0067934 was highly expressed in TC cell lines. It acts as an oncogene, leading to the development of TC by promoting the EMT and “phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)” signaling pathways [113][24]. Knockdown of circ_0067934 inhibited cell proliferation/migration and invasion and enhanced apoptosis [121][31]. By analogy to cell lines, circ_0067934 RNA was also highly expressed in TC compared with adjacent non-cancer tissues. Its overexpression was associated with shorter patient survival. Silencing of this circRNA inhibited cell proliferation and triggered apoptosis, as evidenced by cell counting/Transwell migration assays. Western blot results suggested this knockdown also prevented EMT and PI3K/AKT-pathway-related protein synthesis [113,121][24][31]. CircRNA NRIP1 was upregulated in PTC tissues/cells, and its high levels were associated with advanced PTC stage. Silencing of this circRNA suppressed PTC cell proliferation/invasion while accelerating apoptosis. Overexpression of miR-195-5p inhibited proliferation/invasion capabilities, triggering apoptosis of PTC cell lines, and retained the growth of tumor xenografts. These functions were reversed following circRNA NRIP1 upregulation in PTC cells/tumor xenografts. Protein levels of p38/JAK2/STAT1 were markedly downregulated in miR-195-5p overexpressed PTC cells/tumor xenografts, whereas circRNA NRIP1 overexpression negated these impacts [65][48]. Circ_0079558 and MET were reported to be upregulated in PTC tissues/cell lines. This circRNA promoted PTC cell proliferation/migration and decreased apoptosis through the “miR-26b-5p/MET/AKT” axis [144][49]. Circ-TIAM1 induced cell migration of PTC via the “miR-646/heterogeneous ribonucleoprotein A1 (HNRNPA1)” axis [149][50]. Meanwhile, circNEURL4 downregulation in the PTC samples was directly associated with an unfavorable prognosis. Through binding to miR-1278, circNEURL4 might suppress cell proliferation/invasion of PTC in vivo and in vitro by indirectly increasing the expression of LATS1 [148][51]. Thus, this circRNA could have a clinical diagnostic and/or prognostic utility for PTC patients and a potential targeted therapeutic for PTC via the “miR-1278/LATS1” axis.

2.3. Tumor-Cell-Derived Exosomal circRNAs

Exosomes are created in multivesicular endosomes and can be excreted from several cellular types. They are implicated in intercellular communication by transferring intracellular cargoes, such as proteins/nucleic acids [151][52]. RNA-seq analyses indicated that circRNAs were enriched in the exosomal compartment compared with the original cells [44[53][54],45], and a further study has identified that circRNA levels in exosomes could mirror their levels in cells/tissues [57][55]. Also, circRNAs sorting to exosomes may be controlled by changes in the levels of associated miRNA in producer cells, and the biological activities could be transferred to recipient cells. The abundance of tumor-derived serum “exosomal circRNAs (exo-circRNA)” in xenografted mice was correlated with tumor mass [44][53]. Exo-circRNAs could discriminate patients with colon cancer from healthy controls, suggesting the putative biological function of exosomal circRNAs [92][56]. Emerging evidence shows the excellent promise of exosomal circRNAs in tumor immunity regulation, patient outcome prediction, and drug efficacy evaluation [152][57].

2.4. Circular RNAs and Treatment Resistance

Since the sensitivity of tumors to chemotherapy can impact the survival/prognosis of patients, deciphering the mechanisms underlying drug resistance is critical. Dysregulation of circRNAs in cancer was found to induce chemoresistance. CircHIPK3 overexpression was found to promote gemcitabine (GEM) resistance in pancreatic cancer cells by targeting “RASSF1” through miR-330-5p and was proposed to be a novel biomarker in GEM-resistant PC [154][58]. Similarly, “circRNA Cdr1as” induced apoptosis and increased the cisplatin chemosensitivity of bladder cancer cells both in vitro and in vivo by upregulating “APAF1” expression through miR-1270 inhibition [155][59].

2.5. Functional Enrichment Analysis for the Deregulated Markers

Prior publications have shown the role of deregulated circular RNAs in various hallmarks of cancer (Figure 62). Circ_0001018 activates cell proliferation by regulating the miR-338-3p/SOX4 axis [63][60]. Circ-ITCH and similar circRNAs promote cancer cells, evading antigrowth signals by enhancing other oncogenes, such as CBL [71][25]. CircEIF6/miR-144-3p promotes cancer cells by evading cell death via regulating cellular apoptosis or autophagy [119][27]. Circ-PSD3 limits the replicative potential of cancer cells and impedes apoptosis by regulating HEMGN [109][17]. Circ_0059354/miR-766-3p sustains angiogenesis through regulating ARFGEF1 [123][34]. CiRS-7/miR-7/EGFR [78][30], circ_0067934/PI3K/AKT [121][31], circ_0067934/miR-1301-3p/HMGB1 [146][61], and circ_0062389/miR-1179/HMGB1 [117][62] regulate the EMT process and thus cancer tissue invasion/metastasis.
/media/item_content/202210/6341109a9a9fecancers-14-04728-g006.png
Figure 62. CircRNAs regulate various hallmarks of cancer.
CircRNAs regulate various hallmarks of cancer.

2.6. Genome-Wide Circular RNA Screening

2.6.1. Data Source and Processing

Microarray transcriptomic signature of circRNAs in human PTC was obtained from the “Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/)”. A systematic search revealed a single dataset for circRNA analysis in TC (GSE93522). It contains 18 samples, of which 6 PTCs were compared with their matching contralateral normal thyroid tissues. The platform used was “GPL19978 Agilent-069978 Arraystar Human CircRNA microarray V1”.
The raw data were analyzed via GEO2R software (http://www.ncbi.nlm.nih.gov/geo/geo2r/) using R version 3.2.3 software packages (Biobase 2.30.0, GEOquery 2.40.0, limma 3.26.8), and the results were confirmed using NetworkAnalyst (www.networkanalyst.ca). Differentially expressed circRNA (DEC) analysis was performed using a p-value threshold of <0.05 and log fold change (FC) >1. Annotation files from the platform were used to identify the corresponding circRNA names of the probes, and genes from which circRNAs are derived were identified using circBase (www.circBase.org). A volcano plot was used to visualize the significantly differential circRNAs between PTC and controls. A heatmap was constructed to display the differential circRNA expression patterns among the samples under R version 4.0.3 using the matrix data. DEC was plotted on ideograms using Phenograms (https://ritchielab.org/software/phenogram) (all online tools were last accessed on 23 June 2022).

2.6.2. Identification of Differentially Expressed circRNAs (DEC)

Characteristics of human thyroid specimens are shown in Figure 83A–C. In the current analysis, we i identified 137 significant DEC in PTC compared with controls (Figure 83D). The expression pattern of these DEC enables clear demarcation between cancer and normal thyroid tissues (Figure 83E–F). The top 10 downregulated circRNAs were circ_0000104, circ_0012171, circ_0014161, circ_0000031, circ_0011969, circ_0010832, circ_0010777, circ_0012226, circ_0010395, circ_0011213. The top upregulated genes were circ_0013809, circ_0010146, circ_0011287, circ_0012451, circ_0014700, circ_0040024, circ_0011748, circ_0014566, circ_0014940, circ_0014387 (Figure 83G). Their spliced mature sequence length ranged from 71 to 141,103 base pairs. A total of 74 are transcribed from the antisense strand, whereas 63 DEC are generated from the sense strand. Of 2,895 studied circRNAs, 92.2% (N = 2668) were located along chromosome 1, and 2.38% of genes existed in chromosome 16 (N = 69) (Figure 83H). These included 115 upregulated genes, of which 105 circRNAs lie on chromosome 1. In contrast, the 22 downregulated circRNAs are in chromosome 1. Significant circRNAs were clustered at the short arm of chromosome 1 (1p13.3, 1p32.2), 1q21.3, and 1p34.2 to 1p36.13), long arm of chromosome 1 (1q22), and chromosome 16q22.1. (Figure 83I).
/media/item_content/202210/634110cc9d5cccancers-14-04728-g008.png
Figure 83. Microarray transcriptomic signature of circRNAs in human papillary thyroid carcinoma. (A) Characteristics of six PTC patients were retrieved from the Gene Expression Omnibus database (GSE93522). PTC was compared with their paired contralateral normal thyroid tissues (B) Boxplots showing the distribution of the values of the selected samples. Median-centered values are indicated after log transform and quantile normalization. (C) Principal component analysis for data exploration. The geometrical projection for samples is based on the similarities and differences in the expression of 2895 circRNAs. Samples are plotted across two coordinates; axis 1 explained 52.1% of the variance, whereas axis 2 demonstrated 17% of the data variability. (D) Volcano plot displays statistical significance (−log10 p-value) versus magnitude of change (log2 fold change) in PTC compared with controls. Each dot represents a circRNA. The plot shows 137 significantly differentially expressed circRNAs (DEC): 115 upregulated (red dots) and 22 downregulated (blue dots). Analysis was performed using GEO2R software, with the p-value threshold at <0.05 and log fold changes (FC) at >1. (E) Heatmap for the 12 thyroid tissue specimens using the 137 differentially expressed circRNAs. There was an upregulation pattern of genes in patient samples. Clear differentiation of four PTC tissues and incomplete separation of two others are shown. (F) Principal component analysis to visualize how samples are related to each other. By using the deregulated genes, a complete demarcation was observed between PTC and normal tissues. Axes 1 and 2 explain 66.6% and 9.7% of the variability, respectively. (G) The top-up and downregulated circRNAs in PTC tissues. Derived protein-coding genes from which circRNAs were formed are shown. Fold change values are depicted at the end of the bars. (H) Frequency of tested circRNAs in the microarray according to their chromosomal localization. Y axis is log10 transformed, and the X axis represents the human chromosomes with removed missing chromosomes (chromosomes 18, 21, and Y). (I) Chromosomal ideograms represent the differentially expressed circRNAs annotated with lines in color at specific base-pair locations: blue for upregulated DECs and green for downregulated DECs.

References

  1. Cabanillas, M.E.; McFadden, D.G.; Durante, C. Thyroid cancer. Lancet 2016, 388, 2783–2795.
  2. Kitahara, C.M.; Sosa, J.A. The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 2016, 12, 646–653.
  3. Toraih, E.A.; Fawzy, M.S.; Mohammed, E.A.; Hussein, M.H.; El-Labban, M.M. MicroRNA-196a2 Biomarker and Targetome Network Analysis in Solid Tumors. Mol. Diagn. Ther. 2016, 20, 559–577.
  4. Toraih, E.A.; Aly, N.M.; Abdallah, H.Y.; Al-Qahtani, S.A.; Shaalan, A.A.; Hussein, M.H.; Fawzy, M.S. MicroRNA-target cross-talks: Key players in glioblastoma multiforme. Tumour Biol. 2017, 39, 1010428317726842.
  5. Toraih, E.A.; Mohammed, E.A.; Farrag, S.; Ramsis, N.; Hosny, S. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients. Mol. Diagn. Ther. 2015, 19, 179–190.
  6. Toraih, E.A.; Alghamdi, S.A.; El-Wazir, A.; Hosny, M.; Hussein, M.H.; Khashana, M.; Fawzy, M.S. Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors. PLoS ONE 2018, 13, e0198231.
  7. Hsu, M.-T.; Coca-Prados, M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 1979, 280, 339–340.
  8. Du, W.W.; Fang, L.; Yang, W.; Wu, N.; Awan, F.M.; Yang, Z.; Yang, B.B. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2016, 24, 357–370.
  9. Werfel, S.; Nothjunge, S.; Schwarzmayr, T.; Strom, T.-M.; Meitinger, T.; Engelhardt, S. Characterization of circular RNAs in human, mouse and rat hearts. J. Mol. Cell. Cardiol. 2016, 98, 103–107.
  10. Lasda, E.; Parker, R. Circular RNAs: Diversity of form and function. RNA 2014, 20, 1829–1842.
  11. Capel, B.; Swain, A.; Nicolis, S.; Hacker, A.; Walter, M.; Koopman, P.; Goodfellow, P.; Lovell-Badge, R. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell 1993, 73, 1019–1030.
  12. Cocquerelle, C.; Mascrez, B.; Hétuin, D.; Bailleul, B. Mis-splicing yields circular RNA molecules. FASEB J. 1993, 7, 155–160.
  13. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495, 384–388.
  14. Kristensen, L.S.; Jakobsen, T.; Hager, H.; Kjems, J. The emerging roles of circRNAs in cancer and oncology. Nat. Rev. Clin. Oncol. 2021, 19, 188–206.
  15. Nielsen, A.F.; Bindereif, A.; Bozzoni, I.; Hanan, M.; Hansen, T.B.; Irimia, M.; Kadener, S.; Kristensen, L.S.; Legnini, I.; Morlando, M.; et al. Best practice standards for circular RNA research. Nat. Methods 2022, 1–13.
  16. Jeck, W.R.; Sorrentino, J.A.; Wang, K.; Slevin, M.K.; Burd, C.E.; Liu, J.; Marzluff, W.F.; Sharpless, N.E. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013, 19, 141–157.
  17. Li, Z.; Huang, X.; Liu, A.; Xu, J.; Lai, J.; Guan, H.; Ma, J. Circ_PSD3 promotes the progression of papillary thyroid carcinoma via the miR-637/HEMGN axis. Life Sci. 2021, 264, 118622.
  18. Hu, Z.; Zhao, P.; Zhang, K.; Zang, L.; Liao, H.; Ma, W. Hsa_circ_0011290 regulates proliferation, apoptosis and glycolytic phenotype in papillary thyroid cancer via miR-1252/ FSTL1 signal pathway. Arch. Biochem. Biophys. 2020, 685, 108353.
  19. Yao, Y.; Chen, X.; Yang, H.; Chen, W.; Qian, Y.; Yan, Z.; Liao, T.; Yao, W.; Wu, W.; Yu, T.; et al. Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis. J. Exp. Clin. Cancer Res. 2019, 38, 318.
  20. Zhang, W.; Zhang, H.; Zhao, X. circ_0005273 promotes thyroid carcinoma progression by SOX2 expression. Endocr.-Relat. Cancer 2020, 27, 11–21.
  21. Cai, X.; Zhao, Z.; Dong, J.; Lv, Q.; Yun, B.; Liu, J.; Shen, Y.; Kang, J.; Li, J. Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. Cell Death Dis. 2019, 10, 1–12.
  22. Zhou, G.-K.; Zhang, G.-Y.; Yuan, Z.-N.; Pei, R.; Liu, D.-M. Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8772–8780.
  23. Ma, J.; Kan, Z. Circular RNA circ_0008274 enhances the malignant progression of papillary thyroid carcinoma via modulating solute carrier family 7 member 11 by sponging miR-154-3p. Endocr. J. 2021, 68, 543–552.
  24. Zhang, H.; Ma, X.-P.; Li, X.; Deng, F.-S. Circular RNA circ_0067934 exhaustion expedites cell apoptosis and represses cell proliferation, migration and invasion in thyroid cancer via sponging miR-1304 and regulating CXCR1 expression. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 10851–10866.
  25. Wang, M.; Chen, B.; Ru, Z.; Cong, L. CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem. Biophys. Res. Commun. 2018, 504, 283–288.
  26. Lan, X.; Cao, J.; Xu, J.; Chen, C.; Zheng, C.; Wang, J.; Zhu, X.; Zhu, X.; Ge, M. Decreased expression of hsa_circ_0137287 predicts aggressive clinicopathologic characteristics in papillary thyroid carcinoma. J. Clin. Lab. Anal. 2018, 32, e22573.
  27. Liu, F.; Zhang, J.; Qin, L.; Yang, Z.; Xiong, J.; Zhang, Y.; Li, R.; Li, S.; Wang, H.; Yu, B.; et al. Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. Aging 2018, 10, 3806–3820.
  28. Rong, D.; Sun, H.; Li, Z.; Liu, S.; Dong, C.; Fu, K.; Tang, W.; Cao, H. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget 2017, 8, 73271–73281.
  29. Amicone, L.; Marchetti, A.; Cicchini, C. Exosome-Associated circRNAs as Key Regulators of EMT in Cancer. Cells 2022, 11, 1716.
  30. Han, J.Y.; Guo, S.; Wei, N.; Xue, R.; Li, W.; Dong, G.; Li, J.; Tian, X.; Chen, C.; Qiu, S.; et al. ciRS-7 Promotes the Proliferation and Migration of Papillary Thyroid Cancer by Negatively Regulating the miR-7/Epidermal Growth Factor Receptor Axis. Biomed. Res. Int. 2020, 2020, 9875636.
  31. Wang, H.; Yan, X.; Zhang, H.; Zhan, X. CircRNA circ_0067934 Overexpression Correlates with Poor Prognosis and Promotes Thyroid Carcinoma Progression. Med. Sci. Monit. 2019, 25, 1342–1349.
  32. Liao, J.-Y.; Wu, J.; Wang, Y.-J.; He, J.-H.; Deng, W.-X.; Hu, K.; Zhang, Y.-C.; Zhang, Y.; Yan, H.; Wang, D.-L.; et al. Deep sequencing reveals a global reprogramming of lncRNA transcriptome during EMT. Biochim. Biophys. Acta Mol. Cell Res. 2017, 1864, 1703–1713.
  33. Liu, C.-X.; Li, X.; Nan, F.; Jiang, S.; Gao, X.; Guo, S.-K.; Xue, W.; Cui, Y.; Dong, K.; Ding, H.; et al. Structure and Degradation of Circular RNAs Regulate PKR Activation in Innate Immunity. Cell 2019, 177, 865–880.e21.
  34. Li, Z.; Xu, J.; Guan, H.; Lai, J.; Yang, X.; Ma, J. Circ_0059354 aggravates the progression of papillary thyroid carcinoma by elevating ARFGEF1 through sponging miR-766-3p. J. Endocrinol. Investig. 2021, 45, 825–836.
  35. Cai, Z.; Li, H. Circular RNAs and Bladder Cancer. OncoTargets Ther. 2020, 13, 9573–9586.
  36. Zhong, Z.; Huang, M.; Lv, M.; He, Y.; Duan, C.; Zhang, L.; Chen, J. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017, 403, 305–317.
  37. Zeng, Y.; Xu, Y.; Shu, R.; Sun, L.; Tian, Y.; Shi, C.; Zheng, Z.; Wang, K.; Luo, H. Altered expression profiles of circular RNA in colorectal cancer tissues from patients with lung metastasis. Int. J. Mol. Med. 2017, 40, 1818–1828.
  38. Schweppe, R.E.; Klopper, J.P.; Korch, C.; Pugazhenthi, U.; Benezra, M.; Knauf, J.A.; Fagin, J.A.; Marlow, L.A.; Copland, J.A.; Smallridge, R.C.; et al. Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. J. Clin. Endocrinol. Metab. 2008, 93, 4331–4341.
  39. Fan, Y.X.; Shi, H.Y.; Hu, Y.L.; Jin, X.L. Circ_0000144 facilitates the progression of thyroid cancer via the miR-217/AKT3 pathway. J. Gene Med. 2020, 22, e3269.
  40. Landa, I.; Pozdeyev, N.; Korch, C.; Marlow, L.A.; Smallridge, R.C.; Copland, J.A.; Henderson, Y.C.; Lai, S.Y.; Clayman, G.L.; Onoda, N.; et al. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin. Cancer Res. 2019, 25, 3141–3151.
  41. Fogh, J. Human Tumor Lines for Cancer Research. Cancer Investig. 1986, 4, 157–184.
  42. Peng, N.; Shi, L.; Zhang, Q.; Hu, Y.; Wang, N.; Ye, H. Microarray profiling of circular RNAs in human papillary thyroid carcinoma. PLoS ONE 2017, 12, e0170287.
  43. Ma, W.; Zhao, P.; Zang, L.; Zhang, K.; Liao, H.; Hu, Z. CircTP53 promotes the proliferation of thyroid cancer via targeting miR-1233-3p/MDM2 axis. J. Endocrinol. Investig. 2020, 44, 353–362.
  44. Jin, X.; Wang, Z.; Pang, W.; Zhou, J.; Liang, Y.; Yang, J.; Yang, L.; Zhang, Q. Upregulated hsa_circ_0004458 Contributes to Progression of Papillary Thyroid Carcinoma by Inhibition of miR-885-5p and Activation of RAC1. Med. Sci. Monit. 2018, 24, 5488–5500.
  45. Gui, X.; Li, Y.; Zhang, X.; Su, K.; Cao, W. Circ_LDLR promoted the development of papillary thyroid carcinoma via regulating miR-195-5p/LIPH axis. Cancer Cell Int. 2020, 20, 1–14.
  46. Wei, H.; Pan, L.; Tao, D.; Li, R. Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression. Biochem. Biophys. Res. Commun. 2018, 503, 56–61.
  47. Bi, W.; Huang, J.; Nie, C.; Liu, B.; He, G.; Han, J.; Pang, R.; Ding, Z.; Xu, J.; Zhang, J. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway. J. Exp. Clin. Cancer Res. 2018, 37, 1–9.
  48. Li, C.; Zhu, L.; Fu, L.; Han, M.; Li, Y.; Meng, Z.; Qiu, X. CircRNA NRIP1 promotes papillary thyroid carcinoma progression by sponging mir-195-5p and modulating the P38 MAPK and JAK/STAT pathways. Diagn. Pathol. 2021, 16, 1–11.
  49. Zheng, H.; Fu, Q.; Ma, K.; Shi, S.; Fu, Y. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling. Endocr. J. 2021, 68, 1247–1266.
  50. Zhang, D.; Tao, L.; Xu, N.; Lu, X.; Wang, J.; He, G.; Chu, J. CircRNA circTIAM1 promotes papillary thyroid cancer progression through the miR-646/HNRNPA1 signaling pathway. Cell Death Discov. 2022, 8, 21.
  51. Ding, W.; Shi, Y.; Zhang, H. Circular RNA circNEURL4 inhibits cell proliferation and invasion of papillary thyroid carcinoma by sponging miR-1278 and regulating LATS1 expression. Am. J. Transl. Res. 2021, 13, 5911–5927.
  52. Keller, S.; Sanderson, M.P.; Stoeck, A.; Altevogt, P. Exosomes: From biogenesis and secretion to biological function. Immunol. Lett. 2006, 107, 102–108.
  53. Li, Y.; Zheng, Q.; Bao, C.; Li, S.; Guo, W.; Zhao, J.; Chen, D.; Gu, J.; He, X.; Huang, S. Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. Cell Res. 2015, 25, 981–984.
  54. Dou, Y.; Cha, D.J.; Franklin, J.L.; Higginbotham, J.N.; Jeppesen, D.K.; Weaver, A.M.; Prasad, N.; Levy, S.; Coffey, R.J.; Patton, J.G.; et al. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. Sci. Rep. 2016, 6, 37982.
  55. Dai, X.; Chen, C.; Yang, Q.; Xue, J.; Chen, X.; Sun, B.; Luo, F.; Liu, X.; Xiao, T.; Xu, H.; et al. Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation. Cell Death Dis. 2018, 9, 1–14.
  56. Liu, M.; Wang, Q.; Shen, J.; Yang, B.B.; Ding, X. Circbank: A comprehensive database for circRNA with standard nomenclature. RNA Biol. 2019, 16, 899–905.
  57. Tuo, B.; Chen, Z.; Dang, Q.; Chen, C.; Zhang, H.; Hu, S.; Sun, Z. Roles of exosomal circRNAs in tumour immunity and cancer progression. Cell Death Dis. 2022, 13, 1–9.
  58. Liu, Y.; Xia, L.; Dong, L.; Wang, J.; Xiao, Q.; Yu, X.; Zhu, H. CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1. Cancer Manag. Res. 2020, 12, 921–929.
  59. Yuan, W.; Zhou, R.; Wang, J.; Han, J.; Yang, X.; Yu, H.; Lu, H.; Zhang, X.; Li, P.; Tao, J.; et al. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition. Mol. Oncol. 2019, 13, 1559–1576.
  60. Luo, Q.; Guo, F.; Fu, Q.; Sui, G. hsa_circ_0001018 promotes papillary thyroid cancer by facilitating cell survival, invasion, G1/S cell cycle progression, and repressing cell apoptosis via crosstalk with miR-338-3p and SOX4. Mol. Ther.-Nucleic Acids 2021, 24, 591–609.
  61. Dong, L.-P.; Chen, L.-Y.; Bai, B.; Qi, X.-F.; Liu, J.-N.; Qin, S. circ_0067934 promotes the progression of papillary thyroid carcinoma cells through miR-1301-3p/HMGB1 axis. Neoplasma 2022, 69, 1–15.
  62. Wang, Y.; Zong, H.; Zhou, H. Circular RNA circ_0062389 modulates papillary thyroid carcinoma progression via the miR-1179/high mobility group box 1 axis. Bioengineered 2021, 12, 1484–1494.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback